ALSUntangled #79: alpha-lipoic acid.

Journal: Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
Published:
Abstract

Alpha-lipoic acid (ALA) is a naturally occurring fatty acid. It serves as an essential cofactor for enzymatic reactions in mitochondrial energy production, is a potent antioxidant and has anti-inflammatory effects, which are plausible mechanisms in slowing ALS progression. In ALS preclinical studies, ALA slowed motor function decline and improved survival. There were self-reported cases of improved muscle strength in ALS patients when ALA was taken with numerous additional supplements, making it difficult to discern its efficacy. One small, 6-month open-label study showed improved quality of life, fatigue, and mood after participants took it with B vitamins and amino acids for the first 3 months. So far, no clinical trials have been published in people living with amyotrophic lateral sclerosis (PALS). Given the insufficient clinical data, we cannot endorse ALA and will support more research on its efficacy in slowing ALS progression.

Authors
Alaina Giacobbe, James Hiana, Olivia Wang, Michael Benatar, Paul Wicks, Javier Mascias Cadavid, Sartaj Jhooty, Christopher Mcdermott, Gary Pattee, Tulio Bertorini, Terry Heiman Patterson, Dylan Ratner, Paul Barkhaus, Gregory Carter, Carlayne Jackson, Keelie Denson, Andrew Brown, Carmel Armon, Yuyao Sun, Andre Nguyen, Richard Bedlack, Xiaoyan Li

Similar Publications